A hearing yesterday explained how price controls will impact rare disease R&D—plus, we need to be scared about AMR. (594 words, 2 minutes, 58 seconds)

What happened on the Hill yesterday with PAHPA and R&D amortization—plus, three tips from an expert on making a biotech partnership a success. (717 words, 3 minutes, 35 seconds)

BIO’s Phyllis Arthur will testify at the House Energy and Commerce Health Subcommittee about pandemic preparedness—we’ll recap tomorrow. In the meantime, Merck and the U.S. Chamber of Commerce filed lawsuits calling the drug price controls unconstitutional, and BIO and CSBA released a report highlighting best practices to grow their bioscience sectors. (736 words, 3 minutes, 40 seconds)

FDA advisors voted unanimously on Friday to recommend traditional approval for Leqembi—here’s what happened and the next steps. Plus, while you were convention-ing, there was talk around the world about IP waivers. (671 words, 3 minutes, 20 seconds)

What a week! We catch up on all the news about Mexico, Merck, and Leqembi—plus, give you a few inspiring takeaways from the BIO International Convention. Enjoy the weekend. (623 words, 3 minutes, 6 seconds)

Wednesday at the BIO International Convention was all about policy—from the FDA Commissioner talking about Accelerated Approval and challenges to the FDA’s authority, to panels on price controls and state advocacy. A few highlights below, plus what you might have missed in D.C. this week. (581 words, 2 minutes, 54 seconds)